India’s Drug-Price Agency Rankles Drug Makers
This article was originally published in PharmAsia News
Executive Summary
India's drug-pricing regulator is flexing its muscles in going after drug makers for allegedly charging more for their products than rules allow. The National Pharmaceutical Pricing Authority has been going after drug makers even as the two entities are involved in court litigation over the price limits. The fight between the two entities over price caps has led to a stack of court cases, partly because of a concern of a conflict between regulations and policy. But the chief problem may be a lack of coordination between the NPPA and the country's regulator of quality, the Drug Controller General of India. (Click here for more
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.